Income From Financial Royalty Assets was the largest of Royalty Pharma plc’s 2 reported lines in fiscal 2025, at $2.26B — 95% of $2.38B.
| Product and Service | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Income From Financial Royalty Assets | $2.13B | $2.20B | $2.15B | $2.26B | ||||
| Financial Royalty Assets | — | — | — | — | ||||
| Revenue From Intangible Royalty Assets | — | — | — | — | ||||
| Intangible Royalty Assets | — | — | — | — | ||||
| Other Royalty Income & Revenues | $112.12M | $156.80M | $114.15M | $117.04M | ||||
| Other Royalty Income | — | — | — | — | ||||
| Royalty Income, Other | — | — | — | — | ||||
| Total | $2.24B | $2.35B | $2.26B | $2.38B |
In fiscal 2025, which ended December 31, 2025, the 2 revenue lines Royalty Pharma plc reported in this breakdown added up to $2.38B. That was up 5.1% from $2.26B in fiscal 2024. Income From Financial Royalty Assets was the largest revenue line, at $2.26B or 95.1% of the total, followed by Other Royalty Income & Revenues ($117.04M, 4.9%).
Compared with fiscal 2024, Income From Financial Royalty Assets grew the fastest, rising 5.2% to $2.26B. Over fiscal 2022 to 2025, revenue across these revenue lines went from $2.24B to $2.38B, a compound annual growth rate of 2.1%. Income From Financial Royalty Assets held a steady share of about 95.1%.
The table also keeps 5 revenue lines that Royalty Pharma plc no longer reports, so earlier years can still be read on their original basis; use "Show 5 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2018 to 2025, as reported in Royalty Pharma plc's annual filings.
Royalty Pharma plc (RPRX) breaks its revenue down by revenue line. In fiscal 2025, its largest revenue line was Income From Financial Royalty Assets, with $2.26B or 95.1% of the total, followed by Other Royalty Income & Revenues at $117.04M (4.9%).
Income From Financial Royalty Assets was Royalty Pharma plc's largest revenue line in fiscal 2025, with $2.26B in revenue, 95.1% of the $2.38B reported across its 2 revenue lines.
Of the Royalty Pharma plc revenue lines reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Income From Financial Royalty Assets grew the fastest, rising 5.2% from $2.15B to $2.26B.
Every figure is taken from Royalty Pharma plc's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2018 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.